Entrada registers Phase 2 long-term extension study for DMD exon skipping drugs

Entrada Therapeutics logged one new trial registration this week covering its Duchenne muscular dystrophy pipeline.

• Entrada registered a Phase 2, open-label long-term extension study called "ELEVATE-LTE" (NCT07682129) for ENTR-601-44 and ENTR-601-45 in participants with Duchenne muscular dystrophy amenable to exon skipping. The study is not yet recruiting, with an estimated start of 2026-08 and estimated primary completion in 2032-03.¹ The record lists an estimated enrollment of 80 participants across 17 sites in Belgium, Italy, the Netherlands, Spain, and the United Kingdom.¹ Eligible participants must have completed clinical study ENTR-601-44-201 or ENTR-601-45-201.¹